RxDoctor Payments Data

Valerie Nazarek

Family · West Mifflin, PANPI 1275936114

Payments from drug & device makers

$4,756in general payments, 2019–2025

Across 261 payments — averaging $18.22 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Alkermes, Inc.$1K
  • Neurocrine Biosciences, Inc.$679
  • Teva Pharmaceuticals USA, Inc.$571
  • Johnson & Johnson$428
  • Indivior Inc.$236
  • plus $694 from 9 others

What the payments were for

  • Food & beverage$4,57996%
  • Education$1774%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$4,756 in reported general payments places this provider in the 90th percentile of 4,717 family providers in Pennsylvania.

See all family providers in Pennsylvania

Medicare billing

Part B allowed, 2024
$8,151
Medicare patients
35
Services billed
111

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Invega SustennaPaliperidone Palmitate80$234,015
VraylarCariprazine Hcl93$133,495
IngrezzaValbenazine Tosylate13$101,364
Invega TrinzaPaliperidone Palmitate12$97,948
Abilify MaintenaAripiprazole34$97,859
AristadaAripiprazole Lauroxil35$96,248
LatudaLurasidone Hcl23$30,124
Aripiprazole274$15,447
Risperidone OdtRisperidone13$7,749
Clozapine125$6,645
FetzimaLevomilnacipran Hcl13$6,001
Bupropion XlBupropion Hcl178$3,656
Lurasidone Hcl38$3,411
Trazodone Hcl246$3,281
Quetiapine Fumarate269$3,225

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Johnson & JohnsonInvega Sustenna, Invega Trinza$428$331,96392 claims
AbbVieVraylar, Fetzima$1,133$139,496106 claims
Neurocrine Biosciences, Inc.Ingrezza$679$101,36413 claims
Otsuka America Pharmaceutical, Inc.Abilify Maintena$81$97,85934 claims
Alkermes, Inc.Aristada$1,015$96,24835 claims
Sunovion Pharmaceuticals Inc.Latuda$105$30,12423 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 4,717 family providers in Pennsylvania.

Other family in West Mifflin

See the full list for Pennsylvania

Where these figures come from

Is this you, or does something look wrong? →